Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rosuvastatin - AstraZeneca

Drug Profile

Rosuvastatin - AstraZeneca

Alternative Names: Crestor; CRESTOR OD; Rosuvas; Rosuvastatin calcium; S 4522; ZD 4522

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shionogi
  • Developer AstraZeneca; Shionogi
  • Class Antihyperlipidaemics; Fluorobenzenes; Pyrimidines; Small molecules; Sulfonamides
  • Mechanism of Action HMG-CoA reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Atherosclerosis; Cardiovascular disorders; Hypercholesterolaemia; Hyperlipidaemia; Hypertriglyceridaemia
  • Discontinued Heart failure

Most Recent Events

  • 02 Feb 2023 AstraZeneca and Oslo University withdraws before enrolment phase DECAMERONE II trial in Norway (PO) due to failure to include patients in Depressive disorder (NCT00951132)
  • 12 Feb 2022 Pharmacodynamics data from phase II trial in Cardiovascular disorders presented at the 29th Conference on Retroviruses and Opportunistic Infections (CROI-2022)
  • 25 Jun 2021 Secondary analysis data from the phase III JUPITER trial in Cardiovascular disorders presented at 81st Annual Scientific Sessions of the American Diabetes Association(ADA-2021)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top